Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) EPS (Weighted Average and Diluted) (2022 - 2025)

Axsome Therapeutics' EPS (Weighted Average and Diluted) history spans 4 years, with the latest figure at -$0.55 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 64.29% year-over-year to -$0.55; the TTM value through Dec 2025 reached -$3.68, up 38.56%, while the annual FY2025 figure was -$3.68, 38.56% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.55 at Axsome Therapeutics, up from -$0.94 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.26 in Q1 2023 and bottomed at -$2.13 in Q4 2023.
  • The 4-year median for EPS (Weighted Average and Diluted) is -$1.27 (2023), against an average of -$1.22.
  • The largest annual shift saw EPS (Weighted Average and Diluted) soared 75.47% in 2023 before it plummeted 453.85% in 2024.
  • A 4-year view of EPS (Weighted Average and Diluted) shows it stood at -$1.41 in 2022, then tumbled by 51.06% to -$2.13 in 2023, then grew by 27.7% to -$1.54 in 2024, then surged by 64.29% to -$0.55 in 2025.
  • Per Business Quant, the three most recent readings for AXSM's EPS (Weighted Average and Diluted) are -$0.55 (Q4 2025), -$0.94 (Q3 2025), and -$0.97 (Q2 2025).